Founded to Solve a Real Problem in EV Biomanufacturing.
The EV field has extraordinary potential. What it has lacked is infrastructure. We are building it.
Why Did BioThera Solutions Build an EV Biomanufacturing Platform?
BioThera Solutions was founded to address a critical gap in the extracellular vesicle (EV/exosome) field: the absence of scalable, standardized, and reproducible manufacturing required to bring EV technologies of all kinds into real-world application. We set out to build that infrastructure as a platform, not a single product, and to lay the foundation for every application that comes after the first.
Despite growing scientific evidence for EVs as potent biological delivery systems, the industry has struggled to translate laboratory findings into commercially viable, consistently manufactured products. The problem is not the biology. It is the infrastructure.
We are building that infrastructure, and we started where the need was most immediate. Interest in exosome-based skincare has grown quickly, driven by genuine scientific interest and consumer demand, yet the market is crowded with products making bold claims, backed by inadequate characterization, inconsistent particle concentrations, and little regulatory transparency. There is real demand, and a real absence of material that meets rigorous scientific standards.
BioThera was built to close that gap. We bring biomanufacturing expertise to a space that has been underserved by rigorous science: characterization in line with MISEV2023, measured particle concentrations, and documentation for every batch. Our research and development has produced proprietary, patent-pending technology and the capacity to manufacture at scale. For cosmetic applications, we license our technology exclusively to Vesera™, a skincare company, and produce the material it uses.
Cosmetic applications are where the platform first meets the market, and they are only the beginning. The infrastructure we are building, from manufacturing and characterization to the evidence base, is designed to carry across biological sources and applications. Our current platform uses plant-derived vesicles; as we grow, our research extends to animal-derived sources, including human stem cell-derived vesicles, and to therapeutic applications, an important focus for our team.
Build the integrated extracellular vesicle platform the field has been missing: standardized, characterized vesicles, engineered to work across biological sources, for applications that begin with cosmetics and extend well beyond them.
With cosmetic applications as our first commercial use, we are establishing the manufacturing infrastructure, characterization rigour, and evidence base that credible EV applications, including therapeutic ones, require.
To define what credible, science-led EV technology looks like, and to build the biomanufacturing backbone the extracellular vesicle field needs to mature, across every application it reaches.
We are in the early chapters of the EV era. Our ambition is to set the standard for the field by building the manufacturing foundation, characterization rigour, and evidence base that scientists, clinicians, partners, and regulators can trust.
What Principles Guide BioThera Solutions?
Radical Scientific Transparency
We make no claims we cannot substantiate. Every product specification, characterization result, and regulatory status is communicated with precision. Vague language and marketing hyperbole have no place in how we operate.
Uncompromising Excellence
Manufacturing standards, characterization protocols, formulation quality: we apply the same rigor at every stage, regardless of where we are in the development cycle. Quality is built in, not inspected in.
Innovation
The EV space is early. The manufacturing infrastructure needed to make EVs clinically and commercially viable does not yet fully exist. We are building it. That requires genuine scientific creativity and technical courage.
Execution
Ideas in biotech are plentiful. Rigorous, reliable execution is rare. We close the gap between scientific potential and real-world deployment: consistently, on schedule, and to spec.
Ottawa, Ontario, Canada
BioThera Solutions is headquartered in Ottawa, Ontario. Our location provides proximity to regulatory bodies, a growing life sciences ecosystem, and the clinical and research collaborators central to our work.
477-150 Louis-Pasteur Private Ottawa, Ontario K1N 6N5 Canada
University of Ottawa STEM Complex · Ottawa, Ontario
Company Clarification
BioThera Solutions (Canada) is an independent biotechnology firm specializing in extracellular vesicle (EV) technology. We have no affiliation with Bio-Thera Solutions, Ltd. (China), which focuses on biosimilars and antibody-drug conjugates (ADCs). Our mission is to build the integrated platform that extracellular vesicle technology requires, from research and intellectual property to manufacturing, across the sources and applications of extracellular vesicles.
BioThera Solutions works exclusively with selected partners.
We work selectively with research, clinical and industry partners where there is strong scientific and strategic alignment.
Partnership inquiries are reviewed individually.
Inquire About PartnershipESG and Responsibility
BioThera Solutions operates with environmental, social, and governance (ESG) principles built into how we work. Our current vesicles are derived from medicinal plants rather than animal or human tissue, and our biomanufacturing process is designed to be scalable and resource-efficient. We are transparent about our science and communicate clearly with clinical partners, suppliers, and the broader research community. Our governance practices are aligned with Health Canada cosmetic notification requirements, and our scientific reporting follows MISEV (Minimal Information for Studies of Extracellular Vesicles) guidelines. Sustainability and ethical conduct are part of how we build for the long term.